A software tool for optimizing the solubility of therapeutic proteins.

用于优化治疗性蛋白质溶解度的软件工具。

• 批准号: 7273436
• 负责人: STEVEN T WHITTEN
• 金额: $ 12.18万
• 依托单位: REDSTORMSCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-26 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7273436
• 关键词: Affect; Algorithms; Amino Acid Sequence; Amino Acids; Automation; Base Sequence; Biological Products; Charge; Collaborations; Computational algorithm; Computers; Data; Data Set; Databases; Dependence; Development; Disease; Drug Industry; Engineering; Epidermal Growth Factor; Equation; Erythropoietin; Free Energy; Genetic Variation; Goals; Granulocyte Colony-Stimulating Factor; Helix (Snails); Human; Hydrophobicity; Individual; Length; Leptin; Life; Linux; Malignant Neoplasms; Measurement; Measures; Modeling; Mutation; Output; Pathology; Peptide Sequence Determination; Pharmaceutical Preparations; Pharmacologic Substance; Phase; Phase II Clinical Trials; Process; Property; Proteins; Relative (related person); Research; Resolution; Resources; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Software Tools; Solubility; Solutions; Structural Models; Structure; Sum; System; Testing; Therapeutic; Thermodynamics; Training; United States Food and Drug Administration; Variant; analog; base; blind; clinical efficacy; cytokine; design; ear helix; improved; inhibitor/antagonist; mutant; polypeptide; protein aggregate; protein aggregation; protein folding; protein structure; therapeutic protein

DESCRIPTION (provided by applicant): The therapeutic value of any protein can be easily compromised by low solubility, which often adversely affects purification, yield, activity, shelf-life, and delivery. Solubility concerns are thus frequent obstacles to the development and subsequent FDA approval of pharmaceutical compounds derived from protein models. These facts make the development of a quantifiable description of protein solubility, as well as a design platform that can be used to rationally and efficiently re-engineer therapeutic proteins with increased solubility, a high priority. Previous studies on a database of leptin mutants have shown that a sequence-based analysis of leptin solubility, in which amino acid properties (e.g., hydrophobicity, charge and solvation free energy) are summed over a protein sequence and then correlated to experimental solubility measurements, can provide high predictability (0.96 correlation) for additional mutants when information for similar mutations is already in the training dataset. However, predictability fails for mutation types not found in the training set. In contrast, when ensemble-based parameters derived from structural models of the individual mutants are correlated to the experimental solubilities, predictability readily extends to substitutions unknown to the training set, and shows an apparent structural-thermodynamic component to the solubility of proteins. In a blind test of this model on an additional mutant dataset, the ensemble- based approach predicted whether or not a mutation will increase or decrease leptin solubility with 86% accuracy, with an overall correlation of 0.80 with the actual experimental values. Initial tests also indicate that the ensemble-based parameterization of leptin solubility is readily transferable to non- leptin structures. The goal of this Phase I SBIR is to provide a proof-of-principal of the generality of the ensemble-based model of protein solubility by applying the same parameterization routine used on leptin to a second medically relevant compound, the small mitogenic protein called human epidermal growth factor (EGF). EGF is a target for cancer inhibitor drugs, making analogs designed for optimal solution properties likely to be valuable to the pharmaceutical industry. In a subsequent Phase II project application, a general and automated optimization strategy for therapeutic proteins will be developed using human erythropoietin and human granulocyte-colony stimulating factor as the test systems.

描述（由申请人提供）：任何蛋白质的治疗价值都容易受到低溶解度的影响，这通常会对纯化、产率、活性、保质期和递送产生不利影响。因此，溶解度问题是开发和随后FDA批准衍生自蛋白质模型的药物化合物的常见障碍。这些事实使得开发蛋白质溶解度的可量化描述以及可用于合理有效地重新设计具有增加溶解度的治疗性蛋白质的设计平台成为高度优先事项。先前对瘦素突变体数据库的研究表明，基于序列的瘦素溶解度分析，其中氨基酸特性（例如，疏水性、电荷和溶剂化自由能）在蛋白质序列上相加，然后与实验溶解度测量值相关，当类似突变的信息已经在训练数据集中时，可以为额外的突变体提供高的可预测性（0.96相关性）。然而，对于在训练集中未发现的突变类型，可预测性失败。与此相反，当来自个体突变体的结构模型的基于集合的参数与实验溶解度相关时，可预测性容易地延伸到训练集未知的取代，并显示出蛋白质溶解度的明显的结构-热力学成分。在该模型对另外的突变体数据集的盲测中，基于集合的方法以86%的准确度预测突变是否会增加或减少瘦素溶解度，与实际实验值的总体相关性为0.80。初始测试还表明，瘦素溶解度的基于系综的参数化可容易地转移到非瘦素结构。该I期SBIR的目标是通过将用于瘦素的相同参数化例程应用于第二种医学相关化合物（称为人表皮生长因子（EGF）的小促有丝分裂蛋白）来提供基于整体的蛋白质溶解度模型的一般性的原理证明。EGF是癌症抑制剂药物的靶点，使设计用于最佳溶液性质的类似物可能对制药行业有价值。在随后的II期项目申请中，将使用人促红细胞生成素和人粒细胞集落刺激因子作为测试系统开发治疗性蛋白质的通用和自动化优化策略。